http://purl.org/np/RAnr3oEk4C... RAnr3oEk4C

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

http://www.w3.org/1999/02/22-rdf-syntax-ns#type type

http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement Statement

Leoni Bücken

2021-08-23T11:13:02.533Z

http://purl.org/np/RAnr3oEk4C... RAnr3oEk4C

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

http://www.w3.org/2000/01/rdf-schema#label label

"Eletriptan hydrobromide tablets are contraindicated in patients with: Ischemic coronary artery disease (CAD) (angina pectoris, history of myocardial infarction, or documented silent ischemia) or coronary artery vasospasm, including Prinzmetal's angina [see Warnings and Precautions ( 5.1 )] Wolff-Parkinson-White syndrome or arrhythmias associated with other cardiac accessory conduction pathway disorders [see Warnings and Precautions ( 5.2 )] History of stroke, transient ischemic attack (TIA), or history or current evidence of hemiplegic or basilar migraine because these patients are at a higher risk of stroke [see Warnings and Precautions ( 5.4 )] Peripheral vascular disease [see Warnings and Precautions ( 5.5 )] Ischemic bowel disease [see Warnings and Precautions ( 5.5 )] Uncontrolled hypertension [see Warnings and Precautions ( 5.8 )] Recent use (i.e., within 24 hours) of another 5-hydroxytryptamine 1 1 [see Drug Interactions ( 7.1 )] Hypersensitivity to eletriptan hydrobromide tablets (angioedema and anaphylaxis seen) [see Warnings and Precautions ( 5.9 )] Recent use (i.e., within at least 72 hours) of the following potent CYP3A4 inhibitors: ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, or nelfinavir [see Drug Interactions ( 7.2 ) and Clinical Pharmacology ( 12.3 )] History of coronary artery disease (CAD) or coronary artery vasospasm ( 4 Wolff-Parkinson-White syndrome or other cardiac accessory conduction pathway disorders ( 4 History of stroke, transient ischemic attack, or history or current evidence of hemiplegic or basilar migraine ( 4 Peripheral vascular disease ( 4 Ischemic bowel disease ( 4 Uncontrolled hypertension ( 4 Within 24 hours of treatment with another 5-HT 1 4 Hypersensitivity to eletriptan hydrobromide tablets (angioedema and anaphylaxis seen) ( 4 Within at least 72 hours of treatment with the following potent CYP3A4 inhibitors: ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, or nelfinavir ( 4"

Leoni Bücken

2021-08-23T11:13:02.533Z

http://purl.org/np/RAnr3oEk4C... RAnr3oEk4C

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

http://www.w3.org/1999/02/22-rdf-syntax-ns#object object

http://purl.obolibrary.org/obo/DOID_3393 DOID_3393

Leoni Bücken

2021-08-23T11:13:02.533Z

http://purl.org/np/RAnr3oEk4C... RAnr3oEk4C

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate predicate

https://w3id.org/biolink/vocab/treats treats

Leoni Bücken

2021-08-23T11:13:02.533Z

http://purl.org/np/RAnr3oEk4C... RAnr3oEk4C

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

http://www.w3.org/1999/02/22-rdf-syntax-ns#subject subject

https://identifiers.org/drugbank:DB00216 drugbank:DB00216

Leoni Bücken

2021-08-23T11:13:02.533Z

http://purl.org/np/RAnr3oEk4C... RAnr3oEk4C

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

https://w3id.org/biolink/vocab/provided_by provided_by

https://w3id.org/um/NeuroDKG NeuroDKG

Leoni Bücken

2021-08-23T11:13:02.533Z

http://purl.org/np/RAnr3oEk4C... RAnr3oEk4C

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

https://w3id.org/biolink/vocab/relation relation

https://schema.org/MedicalContraindication MedicalContraindication

Leoni Bücken

2021-08-23T11:13:02.533Z